Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05693818
Other study ID # POS-CTE-003
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 31, 2023
Est. completion date May 15, 2024

Study information

Verified date September 2023
Source Canary Medical
Contact Derek E. Coulter
Phone 18066816979
Email dcoulter@canarymedical.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this prospective study is to demonstrate accuracy of a limp detection model using a healthcare provider assessment as the non-reference standard.


Description:

The primary endpoint of the study is limp severity at the 4-6 week office visit. At 4-6 weeks (+/- 3 days) post-surgery, the healthcare team will assess the patient's limp severity by visual observation on a 3-point Likert scale (0=No limp, 1=Mild/Moderate or 2=Severe).


Recruitment information / eligibility

Status Recruiting
Enrollment 88
Est. completion date May 15, 2024
Est. primary completion date May 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - • Patient must be 18 years of age or older - Independent of study participation, patient is indicated for a commercially available PIQ TKA implant in accordance with product labeling - Patient must be willing and able to complete the protocol required follow-up - Patient has participated in the study-related informed consent process - Patient is willing and able to provide written Informed Consent by signing and dating the IRB approved informed consent Exclusion Criteria: - • Simultaneous bilateral TKA - Staged bilateral TKA less than 6 months from indexed procedure - Patient is a current alcohol or drug abuser - Patient is known to be pregnant, breastfeeding, or considered a member of a protected class (e.g., prisoner, mentally incompetent, etc.) - Patient has a psychiatric illness or cognitive deficit that will not allow proper informed consent and participation in follow-up program - Patient with mental or neurologic conditions who are unwilling or incapable of following postoperative care instructions - Patient with Neuropathic Arthropathy - Patient with any loss of musculature or neuromuscular disease that compromises the affected limb - Patients with known symptomatic foot, hip or spinal injuries and/or conditions that could affect gait

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Clinical Limping Evalution
Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp). If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided.

Locations

Country Name City State
United States Carolina Orthopaedic & Neurosurgical Associates Spartanburg South Carolina

Sponsors (1)

Lead Sponsor Collaborator
Canary Medical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Limp Severity The primary endpoint of the study is limp severity at the 4-6 week office visit. At 4-6 weeks (+/- 3 days) post-surgery, the healthcare team will assess the patient's limp severity by visual observation on a 3-point Likert scale (0=No limp, 1=Mild/Moderate or 2=Severe). 4-6 wks+3 days weeks post TKA
Secondary Test-retest reliability of the Canary Medical Limping Model (CMLM) score Test-retest reliability of the CMLM score from day-to-day and week-to-week. (Specific days and weeks will be provided in the Statistical Analysis Plan.) 4-6 wks+3 days weeks post TKA
Secondary Positive Percent Agreement (PPA) of the CMLM with the healthcare team's assessment Positive Percent Agreement (PPA) 4-6 wks+3 days weeks post TKA
Secondary Negative Percent Agreement (NPA) of the CMLM with the healthcare team's assessment Negative Percent Agreement (NPA) 4-6 wks+3 days weeks post TKA
Secondary Knee Range of Motion ROM will be measured by a goniometer 4-6 wks+3 days weeks post TKA
Secondary Numeric Pain Rating Scale Subjective Pain Measurement 4-6 wks+3 days weeks post TKA
Secondary KOOS Jr Patient Reported outcome 4-6 wks+3 days weeks post TKA
Secondary Limping Self Evaluation Study participants will be asked the following question, "During the past week, have you been limping when walking, because of your knee?" The following answers will be allowed:
Rarely / never
Sometimes or just at first, after sitting for a long time
Often, not just at first
Most of the time
All of the time
4-6 wks+3 days weeks post TKA
See also
  Status Clinical Trial Phase
Recruiting NCT06061367 - Muscles Strength and Gait Parameteres After TKA
Completed NCT04565093 - Efficacy of iPACK After Unilateral TKA N/A
Not yet recruiting NCT05290818 - Total Versus Robotic Assisted Unicompartmental Knee Replacement N/A
Terminated NCT03253224 - Magnesium and Postoperative Pain Phase 4
Completed NCT04956393 - The SOAR (Stop OsteoARthritis) Program Proof-of-Concept Study N/A
Not yet recruiting NCT04479462 - The Establishment of Total Joint Arthroplasty Registry Database
Terminated NCT04712019 - Evaluating Edema and Range of Motion Using Negative Pressure Therapy vs. Standard Surgical Dressing in Bilateral TKA N/A
Completed NCT04648072 - How Does the Addition of Adductor Canal Block to Local Infiltration Affect Recovery in Patients Undergoing Total Knee Arthroplasty? A Feasibility Study. N/A
Withdrawn NCT03704558 - Preoperative Radiographic Evaluation of Medial Tibiofemoral Knee Osteoarthritis
Not yet recruiting NCT06024161 - Weight Change and the Risk of Chronic Pain Following Hip and Knee Arthroplasties
Not yet recruiting NCT05900791 - Persistent Pain After Knee Replacement
Completed NCT06196359 - Assessing Function and Pain After Total Knee Arthroplasty With Combined Femoral and Popliteal Nerve Block N/A
Completed NCT05065775 - Bioavailability of Intranasal Dexmedetomidine Phase 4
Completed NCT04923724 - Tourniquet on Total Knee Arthroplasty N/A
Completed NCT03540667 - Study of Hip and Knee Arthroplasty in South Africa
Completed NCT04388111 - Intraosseous Morphine in Primary TKA Phase 4
Completed NCT04441112 - Intraarticular Injections of the Hip and Knee With Triamcinolone Versus Ketorolac: A Randomized Controlled Trial Phase 2/Phase 3
Not yet recruiting NCT03874468 - Prevalence of Coronal Femoral Bowing in the Egyptian Arthritic Knee
Not yet recruiting NCT05760534 - Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia Phase 4
Completed NCT04814706 - Gastric Volume in Elderly Patients Undergoing Staged Bilateral Total Knee Arthroplasty